{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:00:41Z","timestamp":1788454841730,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Research and application of clinical characteristic diagnosis and treatment technology in Beijing","award":["Z221100007422032"],"award-info":[{"award-number":["Z221100007422032"]}]},{"name":"Research and application of clinical characteristic diagnosis and treatment technology in Beijing","award":["Z221100007422032"],"award-info":[{"award-number":["Z221100007422032"]}]},{"name":"Research and application of clinical characteristic diagnosis and treatment technology in Beijing","award":["Z221100007422032"],"award-info":[{"award-number":["Z221100007422032"]}]},{"name":"Beijing Natural Science Foundation","award":["Z230021"],"award-info":[{"award-number":["Z230021"]}]},{"name":"Beijing Natural Science Foundation","award":["Z230021"],"award-info":[{"award-number":["Z230021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00210-025-03982-7","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T06:04:24Z","timestamp":1740981864000},"page":"10719-10729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tacrolimus population pharmacokinetic model\u2013informed precision dosing in adult liver transplant patients"],"prefix":"10.1007","volume":"398","author":[{"given":"Jiana","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"3982_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/bcp.12174","volume":"77","author":"MH Abdel Jalil","year":"2014","unstructured":"Abdel Jalil MH, Hawwa AF, McKiernan PJ et al (2014) Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. Brit J Clin Pharmacol 77:130\u2013140. https:\/\/doi.org\/10.1111\/bcp.12174","journal-title":"Brit J Clin Pharmacol"},{"key":"3982_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-005-0933-6","volume":"61","author":"M Antignac","year":"2005","unstructured":"Antignac M, Hulot JS, Boleslawski E et al (2005) Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol 61:409\u2013416. https:\/\/doi.org\/10.1007\/s00228-005-0933-6","journal-title":"Eur J Clin Pharmacol"},{"key":"3982_CR3","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.transproceed.2015.09.024","volume":"47","author":"A Argudo","year":"2015","unstructured":"Argudo A, Gonz\u00e1lez De Aledo JM, Al\u00eda P et al (2015) Liver transplant patient carriers of polymorphism cyp3a5*1 donors may need more doses of tacrolimus from the first month after transplantation. Transplant Proc 47:2388\u20132392. https:\/\/doi.org\/10.1016\/j.transproceed.2015.09.024","journal-title":"Transplant Proc"},{"key":"3982_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3969\/j.issn.1674-7445.2019.03.001","volume":"10","author":"Branch of Organ Transplantation of Chinese Medical Association","year":"2019","unstructured":"Branch of Organ Transplantation of Chinese Medical Association (2019) Technical specification for clinical application of immunosuppressive agents in organ transplantation (2019 edition). Organ Transplant 10:213\u201326. https:\/\/doi.org\/10.3969\/j.issn.1674-7445.2019.03.001","journal-title":"Organ Transplant"},{"key":"3982_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3969\/j.issn.1674-7445.2021.01.002","volume":"12","author":"Branch of Organ Transplantation of Chinese Medical Association","year":"2021","unstructured":"Branch of Organ Transplantation of Chinese Medical Association (2021) Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition). Organ Transplant 12:8\u201314. https:\/\/doi.org\/10.3969\/j.issn.1674-7445.2021.01.002","journal-title":"Organ Transplant"},{"key":"3982_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/1735-5362.301335","volume":"15","author":"D Brocks","year":"2020","unstructured":"Brocks D, Hamdy D (2020) Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring. Res Pharma Sci 15:503\u2013514. https:\/\/doi.org\/10.4103\/1735-5362.301335","journal-title":"Res Pharma Sci"},{"key":"3982_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jcpt.12599","volume":"42","author":"B Chen","year":"2017","unstructured":"Chen B, Shi HQ, Liu XX et al (2017) Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther 42:679\u2013688. https:\/\/doi.org\/10.1111\/jcpt.12599","journal-title":"J Clin Pharm Ther"},{"key":"3982_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.21037\/tp-20-84","volume":"9","author":"X Chen","year":"2020","unstructured":"Chen X, Wang D-D, Xu H et al (2020) Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation. Transl Pediatr 9:576\u2013586. https:\/\/doi.org\/10.21037\/tp-20-84","journal-title":"Transl Pediatr"},{"key":"3982_CR9","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3969\/j.issn.1001-5256.2015.09.002","volume":"31","author":"Chinese Society of Organ Transplantation, Chinese Medical Association","year":"2015","unstructured":"Chinese Society of Organ Transplantation, Chinese Medical Association (2015) Guidelines for application of tacrolimus in clinical liver transplantation. J Clin Hepatol 31:1372\u20131374. https:\/\/doi.org\/10.3969\/j.issn.1001-5256.2015.09.002","journal-title":"J Clin Hepatol"},{"key":"3982_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s002280100331","volume":"57","author":"S Fukatsu","year":"2001","unstructured":"Fukatsu S, Yano I, Igarashi T et al (2001) Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 57:479\u201384. https:\/\/doi.org\/10.1007\/s002280100331","journal-title":"Eur J Clin Pharmacol"},{"key":"3982_CR11","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2165\/00003088-200342130-00006","volume":"42","author":"M Fukudo","year":"2003","unstructured":"Fukudo M, Yano I, Fukatsu S et al (2003) Forecasting of blood tacrolimus concentrations based on the Bayesian Method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet. 42:1161\u201378. https:\/\/doi.org\/10.2165\/00003088-200342130-00006","journal-title":"Clin Pharmacokinet."},{"key":"3982_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00228-013-1501-0","volume":"69","author":"V Guy-Viterbo","year":"2013","unstructured":"Guy-Viterbo V, Scohy A, Verbeeck RK et al (2013) Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol 69:1533\u20131542. https:\/\/doi.org\/10.1007\/s00228-013-1501-0","journal-title":"Eur J Clin Pharmacol"},{"key":"3982_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/pgs.14.75","volume":"15","author":"V Guy-Viterbo","year":"2014","unstructured":"Guy-Viterbo V, Baudet H, Elens L et al (2014) Influence of donor\u2013recipient CYP3A4\/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics 15:1207\u20131221. https:\/\/doi.org\/10.2217\/pgs.14.75","journal-title":"Pharmacogenomics"},{"key":"3982_CR14","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2147\/TCRM.S184376","volume":"14","author":"E Ji","year":"2018","unstructured":"Ji E, Kim MG, Oh JM (2018) CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag 14:2119\u20132126. https:\/\/doi.org\/10.2147\/TCRM.S184376","journal-title":"Ther Clin Risk Manag"},{"key":"3982_CR15","doi-asserted-by":"publisher","first-page":"131550","DOI":"10.1016\/j.chemosphere.2021.131550","volume":"286","author":"L Jing","year":"2022","unstructured":"Jing L, Sun Y, Wang J et al (2022) Oxidative stress and endoplasmic reticulum stress contributed to hepatotoxicity of decabromodiphenyl ethane (DBDPE) in L-02 cells. Chemosphere 286:131550. https:\/\/doi.org\/10.1016\/j.chemosphere.2021.131550","journal-title":"Chemosphere"},{"key":"3982_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/bcp.15909","volume":"90","author":"K Khamlek","year":"2024","unstructured":"Khamlek K, Komenkul V, Sriboonruang T et al (2024) Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: a systematic review. Brit J Clin Pharmacol 90:406\u2013426. https:\/\/doi.org\/10.1111\/bcp.15909","journal-title":"Brit J Clin Pharmacol"},{"key":"3982_CR17","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S et al (2020) Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin Pharmacokinet 59:1357\u20131392. https:\/\/doi.org\/10.1007\/s40262-020-00922-x","journal-title":"Clin Pharmacokinet"},{"key":"3982_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13098-023-01000-5","volume":"15","author":"J Kwak","year":"2023","unstructured":"Kwak J, Seo I-H, Lee Y-J (2023) Serum \u03b3-glutamyltransferase level and incidence risk of metabolic syndrome in community dwelling adults: longitudinal findings over 12 years. Diabetol Metab Syndr 15:29. https:\/\/doi.org\/10.1186\/s13098-023-01000-5","journal-title":"Diabetol Metab Syndr"},{"key":"3982_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1592\/phco.26.8.1069","volume":"26","author":"JY Lee","year":"2006","unstructured":"Lee JY, Hahn HJ, Son IJ et al (2006) Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy 26:1069\u20131077. https:\/\/doi.org\/10.1592\/phco.26.8.1069","journal-title":"Pharmacotherapy"},{"key":"3982_CR20","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2710.2007.00850.x","volume":"32","author":"D Li","year":"2007","unstructured":"Li D, Lu W, Zhu J-Y et al (2007) Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients: tacrolimus population pharmacokinetics and CYP3A5. J Clin Pharm Ther 32:505\u2013515. https:\/\/doi.org\/10.1111\/j.1365-2710.2007.00850.x","journal-title":"J Clin Pharm Ther"},{"key":"3982_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00007691-200104000-00006","volume":"23","author":"M Macchi-Andanson","year":"2001","unstructured":"Macchi-Andanson M, Charpiat B, Jelliffe RW et al (2001) Failure of Traditional Trough Levels to Predict Tacrolimus Concentrations. Ther Drug Monit 23:129\u2013133. https:\/\/doi.org\/10.1097\/00007691-200104000-00006","journal-title":"Ther Drug Monit"},{"key":"3982_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","volume":"72","author":"DJAR Moes","year":"2016","unstructured":"Moes DJAR, Van Der Bent SAS, Swen JJ et al (2016) Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol 72:163\u2013174. https:\/\/doi.org\/10.1007\/s00228-015-1963-3","journal-title":"Eur J Clin Pharmacol"},{"key":"3982_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0090-9556(24)15298-1","volume":"27","author":"A M\u00f6ller","year":"1999","unstructured":"M\u00f6ller A, Iwasaki K, Kawamura A et al (1999) The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 27:633\u2013636","journal-title":"Drug Metab Dispos"},{"key":"3982_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/FTD.0b013e31829dcbcd","volume":"36","author":"FT Musuamba","year":"2014","unstructured":"Musuamba FT, Guy-Viterbo V, Reding R et al (2014) Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. Ther Drug Monit 36:54\u201361. https:\/\/doi.org\/10.1097\/FTD.0b013e31829dcbcd","journal-title":"Ther Drug Monit"},{"key":"3982_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-012-1300-z","volume":"69","author":"I Oteo","year":"2013","unstructured":"Oteo I, Lukas JC, Leal N et al (2013) Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol 69:65\u201374. https:\/\/doi.org\/10.1007\/s00228-012-1300-z","journal-title":"Eur J Clin Pharmacol"},{"key":"3982_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/00003088-200140010-00005","volume":"40","author":"MJ Sanchez","year":"2001","unstructured":"Sanchez MJ, Manzanares C, Santos-Buelga D et al (2001) Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion Therapy. Clin Pharmacokinet 40:63\u201371. https:\/\/doi.org\/10.2165\/00003088-200140010-00005","journal-title":"Clin Pharmacokinet"},{"key":"3982_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/1060028019897050","volume":"54","author":"J Shao","year":"2020","unstructured":"Shao J, Wang C, Fu P et al (2020) Impact of donor and recipient CYP3A5*3 genotype on tacrolimus population pharmacokinetics in Chinese adult liver transplant recipients. Ann Pharmacother 54:652\u2013661. https:\/\/doi.org\/10.1177\/1060028019897050","journal-title":"Ann Pharmacother"},{"key":"3982_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/jlts.2003.50023","volume":"9","author":"C Staatz","year":"2003","unstructured":"Staatz C (2003) Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 9:130\u2013137. https:\/\/doi.org\/10.1053\/jlts.2003.50023","journal-title":"Liver Transpl"},{"key":"3982_CR29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/00007890-200109270-00013","volume":"72","author":"CE Staatz","year":"2001","unstructured":"Staatz CE, Taylor PJ, Lynch SV et al (2001) Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 72:1056\u20131061. https:\/\/doi.org\/10.1097\/00007890-200109270-00013","journal-title":"Transplantation"},{"key":"3982_CR30","doi-asserted-by":"publisher","first-page":"606","DOI":"10.5414\/CP201800","volume":"51","author":"N Valdivieso","year":"2013","unstructured":"Valdivieso N, Oteo I, Valdivieso A et al (2013) Tacrolimus dose individualization in de novo patients after 10 years of experience in liver transplantation: pharmacokinetic considerations and patient pathophysiology. Int J Clin Pharmacol Ther 51:606\u2013614. https:\/\/doi.org\/10.5414\/CP201800","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3982_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0b013e31823415cc","volume":"33","author":"JE Wallin","year":"2011","unstructured":"Wallin JE, Bergstrand M, Wilczek HE et al (2011) Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit 33:663\u2013672. https:\/\/doi.org\/10.1097\/FTD.0b013e31823415cc","journal-title":"Ther Drug Monit"},{"key":"3982_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5414\/CP202189","volume":"53","author":"J Yang","year":"2015","unstructured":"Yang J, Liao S, Zhu L et al (2015) Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. Int J Clin Pharmacol Ther 53:75\u201383. https:\/\/doi.org\/10.5414\/CP202189","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3982_CR33","doi-asserted-by":"publisher","first-page":"713650","DOI":"10.1155\/2014\/713650","volume":"2014","author":"L Zhu","year":"2014","unstructured":"Zhu L, Wang H, Sun X et al (2014) The population pharmacokinetic models of tacrolimus in Chinese adult liver transplantation patients. J Pharm (Cairo) 2014:713650. https:\/\/doi.org\/10.1155\/2014\/713650","journal-title":"J Pharm (Cairo)"},{"key":"3982_CR34","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3109\/00498254.2015.1021733","volume":"45","author":"L Zhu","year":"2015","unstructured":"Zhu L, Yang J, Zhang Y et al (2015) Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T\/A polymorphism on pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Xenobiotica 45:840\u2013846. https:\/\/doi.org\/10.3109\/00498254.2015.1021733","journal-title":"Xenobiotica"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03982-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03982-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03982-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T06:54:51Z","timestamp":1757141691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03982-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3982"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03982-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was carried out with the official endorsement of the institutional ethics committee of Beijing Friendship Hospital, Capital Medical University (2022-P2-341\u201301).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}